Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-043469

Karyopharm Therapeutics Inc. · KPTI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Michael Kauffman
Officer — Chief Executive Officer · Director
Period of report
Jul 18, 2018
Accepted (ET)
Jul 20, 2018 · 4:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockJul 18, 2018M1$0.033A512,144D
Common StockJul 18, 2018M5,757$0.264A517,901D
Common StockJul 18, 2018M4,242$4.752A522,143D
Common StockF2Jul 18, 2018S10,000$18.2686D512,143D
Common Stockholding———713,510IBy Spouse
Common StockF3holding———47,309IBy GRAT
Common StockF4holding———47,309IBy Spouse's GRAT

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F5$0.033Jul 18, 2018M1D—Dec 31, 2020Common Stock10D
Stock Option (right to buy)F6$0.264Jul 18, 2018M5,757D—Dec 13, 2021Common Stock5,7570D
Stock Option (right to buy)F7$4.752Jul 18, 2018M4,242D—Sep 2, 2023Common Stock4,242476,061D

Explanation of responses